Trial Profile
An Exploratory Study Assessing the Short Term Predictors of Remission of Voclosporin 23.7mg Twice Daily (BID) in Combination With Standard of Care in Patients With Active Lupus Nephritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Voclosporin (Primary) ; Corticosteroids; Mycophenolate mofetil
- Indications Lupus nephritis
- Focus Biomarker; Proof of concept; Therapeutic Use
- Acronyms AURION
- Sponsors Aurinia Pharmaceuticals
- 17 Mar 2021 Number of Participants With Reduction or Normalization of Anti ds DNA, C3 and C4, have been introduced as new primary end-points in addition to the existing one (Urine Protein/Creatinine Ratio (UPCR)).
- 18 Sep 2017 Status changed from active, no longer recruiting to completed.
- 27 Mar 2017 Results at week 48 published in an Aurinia Pharmaceuticals media release.